ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1847

Certolizumab-Pegol Induces Reverse Signaling Through Membrane TNF Via Calcineurin Activation In Human Monocytes. Relevance In Inflammation

Jean-Frederic Boyer1,2, Michel Baron3, Delphine Nigon1, Arnaud L. Constantin1, Alain G. Cantagrel1,2 and Jean-Luc Davignon2,4, 1Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France, 2INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Toulouse, France, 3Centre de Physiopathologie de Toulouse Purpan, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Toulouse, France, 4Rheumatology, Purpan University Hospital, Toulouse, France

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Anti-TNF therapy and monocytes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Reverse signalling seems to play a role in the mode of action of anti-TNF-α agents but this pathway and its relevance are poorly understood. CD36 is a scavenger receptor implicated in the phagocytosis of senescent cells at the end of the inflammatory process. We previously demonstrated that TNF-α inhibitors increase CD36 expression in human monocytes and our results suggest a reverse signalling pathway. Casein kinase 1 phosphorylation of serine localized in the intra-cytoplasmic tail of membrane TNF-α (tmTNF) has been reported to play a role in reverse signalling. Our aim was to clarify the pathway engaged in reverse signalling induced by certolizumab-pegol and its relevance on TNF receptor (TNFR) and TLR4 signalling.

Methods:

Human monocytes were isolated from peripheral blood mononuclear cells of healthy donors by plastic adherence or negative selection. The consequence of dephosphorylation of tmTNF in CD36 induction was assessed using a specific casein-kinase 1 inhibitor D4476. We searched for a putative phosphatase using cyclosporine A, a specific inhibitor of calcineurin phosphatase. An inhibitor of the endopeptidase SPPL2b, ZLL-2 ketone, was used to asses intra-membrane proteolysis of tm-TNF. CD36 and expression was analyzed by RT-qPCR and flow cytometry. IL-1 expression was induced by LPS and analysed by RT-PCR and western blot. Experiments were done at least 3 times in duplicate. Data were analyzed by Wilcoxon test matched-pairs signed-rank test and Student’s paired t-test.

Results:

Certolizumab-pegol and D4476 used separately respectively increased the expression of CD36. The association of both compounds potentiated this increase (p=0.02). This suggested the role of casein kinase I in the down-regulation tmTNF. The calcineurin inhibitor cyclosporine strongly inhibited the induction of CD36 observed with certolizumab-pegol (p=0.02), However, the inhibitor of intra-membrane clivage of tmTNF, ZLL-2, did not modify the induction of CD36 induced by certolizumab-pegol (p=0.2). Moreover a transfection of TNF-α linked with GFP in its intracytoplasmic tail failed to show any nuclear translocation in presence of certolizumab-pegol. These data demonstrated the absence of intramembrane proteolysis in reverse signalling induced by anti-TNF-α. IL-1 expression induced by LPS was significantly decreased by certolizumab-pegol, and this effect was inhibited by the calcineurin inhibitor cyclosporine A. Furthermore, TNFR2 did not play a role in the reverse signalling induced by tmTNF.

Conclusion:

Certolizumab-pegol induced reverse signalling in human monocytes through tm-TNF. This resulted in increased CD36 expression, down-modulation of IL-1 production induced byTLR4, but had no effect on TNFR2 signalling. Dephosphorylation of tmTNF as well as calcineurin activation were involved in certolizumab-pegol-induced reverse signalling. Taken together, these results suggest a role of reverse signalling in the regulation of inflammation by anti-TNF-α.


Disclosure:

J. F. Boyer,
None;

M. Baron,
None;

D. Nigon,
None;

A. L. Constantin,
None;

A. G. Cantagrel,
None;

J. L. Davignon,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/certolizumab-pegol-induces-reverse-signaling-through-membrane-tnf-via-calcineurin-activation-in-human-monocytes-relevance-in-inflammation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology